Table 1 Demographic characteristics of patients in the reports
Variables | Triple anti-thrombotic therapies (n = 812) | Dual antiplatelets (n = 3820) | Acetylsalicylic acid (n = 3098) | Clopidogrel (n = 12897) | ||
|---|---|---|---|---|---|---|
Age categories [n (%)] | ≤ 17 years | None | 5 (0.1) | 36 (1.2) | 15 (0.1) | |
18–64 years | 157 (19.3) | 945 (24.7) | 768 (24.8) | 2179 (16.9) | ||
≥ 65 years | 504 (62.1) | 2018 (52.8) | 1602 (51.7) | 6284 (48.7) | ||
Not reported | 151 (18.6) | 852 (22.3) | 692 (22.3) | 4419 (34.3) | ||
Mean (SD) age (years) | 70.9 (10.9) | 69 (12.6) | 67.8 (16.9) | 71.8 (12.6) | ||
Median (range) age (years) | 72 (31–100) | 70 (1-100) | 71 (0-100) | 74 (0-103) | ||
Gender distribution [n (%)] | Male | 507 (61.2) | 2211 (57.9) | 1562 (50.4) | 6036 (46.8) | |
Female | 256 (31.5) | 1366 (35.7) | 1256 (40.5) | 3885 (30.1) | ||
Unknown | 59 (7.3) | 243 (6.4) | 280 (9.1) | 2976 (23.1) | ||
Year of receiving the report [n (%)] | 2004–2008 | 177 (21.8) | 1551 (40.6) | 1168 (37.7) | 694 (5.4) | |
2009–2012 | 314 (38.7) | 1621 (42.4) | 1009 (32.6) | 570 (4.4) | ||
2013–2016 | 62 (7.6) | 174 (4.6) | 163 (5.3) | 4758 (36.9) | ||
2017–2020 | 196 (24.1) | 306 (8) | 602 (19.4) | 4052 (31.4) | ||
2021–2024 (June) | 63 (7.8) | 166 (4.3) | 156 (5) | 2823 (21.9) | ||
Top reporting countries [n (%)] | USA | 568 (70) | 2117 (55.4) | 1727 (55.7) | 5928 (46) | |
Others | 254 (30) | 1703 (45.6) | 1371 (44.3) | 6969 (54) | ||